Vikram Purohit
Stock Analyst at Morgan Stanley
(0.80)
# 2,865
Out of 4,412 analysts
153
Total ratings
24.07%
Success rate
-23.16%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAI Exscientia | Maintains: Equal-Weight | $7 | $4.03 | +73.70% | 16 | Apr 22, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 | $135.90 | -14.64% | 17 | Apr 22, 2024 | |
| ABVX Abivax | Maintains: Equal-Weight | $15 → $16 | $15.78 | +1.39% | 2 | Apr 11, 2024 | |
| CMPS COMPASS Pathways | Initiates: Overweight | $30 | $7.94 | +277.83% | 1 | Apr 1, 2024 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $20 → $22 | $13.69 | +60.70% | 6 | Feb 28, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $61 → $59 | $38.57 | +52.97% | 5 | Dec 26, 2023 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $19 → $13 | $4.24 | +206.60% | 6 | Nov 29, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $10 → $6 | $5.49 | +9.29% | 7 | Nov 13, 2023 | |
| VTYX Ventyx Biosciences | Downgrades: Equal-Weight | $46 → $6 | $3.93 | +52.67% | 1 | Nov 7, 2023 | |
| INCY Incyte | Maintains: Equal-Weight | $74 → $64 | $51.68 | +23.84% | 15 | Nov 1, 2023 | |
| RGNX REGENXBIO | Maintains: Overweight | $43 → $42 | $16.19 | +159.42% | 8 | Aug 29, 2023 | |
| EVLO Evelo Biosciences | Maintains: Equal-Weight | $2 → $10 | $0.05 | +20,102.02% | 4 | Jul 26, 2023 | |
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $8.12 | +35.47% | 1 | Jul 13, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Equal-Weight | $87 → $90 | $71.71 | +25.51% | 16 | Jun 12, 2023 | |
| HOOK HOOKIPA Pharma | Maintains: Equal-Weight | $2 → $2.25 | $0.89 | +151.88% | 3 | Jun 5, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Overweight | $51 → $50 | $8.47 | +490.32% | 5 | Mar 1, 2023 | |
| AKLI Akili | Maintains: Equal-Weight | $2 → $3 | $0.25 | +1,124.49% | 2 | Jan 25, 2023 | |
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $38 → $41 | $33.37 | +22.86% | 9 | Dec 19, 2022 | |
| TIL Instil Bio | Maintains: Equal-Weight | $120 → $40 | $10.60 | +277.36% | 7 | Dec 12, 2022 | |
| PROK ProKidney | Initiates: Equal-Weight | $13 | $2.12 | +513.21% | 1 | Nov 10, 2022 | |
| SDGR Schrödinger | Maintains: Equal-Weight | $39 → $38 | $23.97 | +58.53% | 5 | Nov 4, 2022 | |
| CERT Certara | Maintains: Equal-Weight | $24 → $20 | $16.57 | +20.70% | 4 | Aug 24, 2022 | |
| TBPH Theravance Biopharma | Maintains: Underweight | $11 → $10 | $9.12 | +9.65% | 7 | Jul 25, 2022 | |
| RDUS Radius Health | Downgrades: Underweight | n/a | $17.90 | - | 3 | Dec 10, 2021 | |
| TCRX TScan Therapeutics | Initiates: Overweight | n/a | $7.32 | - | 1 | Aug 10, 2021 | |
| DBVT DBV Technologies | Maintains: Equal-Weight | n/a | $0.68 | - | 1 | Mar 18, 2020 |
Exscientia
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $7
Current: $4.03
Upside: +73.70%
Ascendis Pharma
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $116
Current: $135.90
Upside: -14.64%
Abivax
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $15.78
Upside: +1.39%
COMPASS Pathways
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $7.94
Upside: +277.83%
Sage Therapeutics
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $13.69
Upside: +60.70%
Halozyme Therapeutics
Dec 26, 2023
Maintains: Overweight
Price Target: $61 → $59
Current: $38.57
Upside: +52.97%
Acelyrin
Nov 29, 2023
Maintains: Equal-Weight
Price Target: $19 → $13
Current: $4.24
Upside: +206.60%
Foghorn Therapeutics
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $10 → $6
Current: $5.49
Upside: +9.29%
Ventyx Biosciences
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $3.93
Upside: +52.67%
Incyte
Nov 1, 2023
Maintains: Equal-Weight
Price Target: $74 → $64
Current: $51.68
Upside: +23.84%
REGENXBIO
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $16.19
Upside: +159.42%
Evelo Biosciences
Jul 26, 2023
Maintains: Equal-Weight
Price Target: $2 → $10
Current: $0.05
Upside: +20,102.02%
Recursion Pharmaceuticals
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.12
Upside: +35.47%
Axsome Therapeutics
Jun 12, 2023
Maintains: Equal-Weight
Price Target: $87 → $90
Current: $71.71
Upside: +25.51%
HOOKIPA Pharma
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $2 → $2.25
Current: $0.89
Upside: +151.88%
Arcutis Biotherapeutics
Mar 1, 2023
Maintains: Overweight
Price Target: $51 → $50
Current: $8.47
Upside: +490.32%
Akili
Jan 25, 2023
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $0.25
Upside: +1,124.49%
Kymera Therapeutics
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $33.37
Upside: +22.86%
Instil Bio
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $10.60
Upside: +277.36%
ProKidney
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.12
Upside: +513.21%
Schrödinger
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $23.97
Upside: +58.53%
Certara
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $16.57
Upside: +20.70%
Theravance Biopharma
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.12
Upside: +9.65%
Radius Health
Dec 10, 2021
Downgrades: Underweight
Price Target: n/a
Current: $17.90
Upside: -
TScan Therapeutics
Aug 10, 2021
Initiates: Overweight
Price Target: n/a
Current: $7.32
Upside: -
DBV Technologies
Mar 18, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $0.68
Upside: -